Despite the high prevalence of KRAS mutations and RTK activation in lung adenocarcinomas (and other forms of non-small cell lung cancers), small cell lung carcinomas are characterized by nearly universal inactivation of TP53 and RB1 through mutation or deletion, without alterations in RAS (41). Here, KRAS is linked to lung adenocarcinoma.